



# A phospho-proteomic study of cetuximab resistance in *KRAS/NRAS/BRAF<sup>V600</sup>* wild-type colorectal cancer

Alexandros Georgiou<sup>1,4</sup> · Adam Stewart<sup>1</sup> · Georgios Vlachogiannis<sup>2</sup> · Lisa Pickard<sup>1</sup> · Nicola Valeri<sup>2,4</sup> · David Cunningham<sup>4</sup> · Steven R. Whittaker<sup>1</sup> · Udai Banerji<sup>1,3</sup>

Accepted: 27 July 2021  
© Crown 2021

## Abstract

**Purpose** We hypothesised that plasticity in signal transduction may be a mechanism of drug resistance and tested this hypothesis in the setting of cetuximab resistance in patients with *KRAS/NRAS/BRAF<sup>V600</sup>* wild-type colorectal cancer (CRC).

**Methods** A multiplex antibody-based platform was used to study simultaneous changes in signal transduction of 55 phospho-proteins in 12 *KRAS/NRAS/BRAF<sup>V600</sup>* wild-type CRC cell lines (6 cetuximab sensitive versus 6 cetuximab resistant) following 1 and 4 h in vitro cetuximab exposure. We validated our results in CRC patient samples (n=4) using ex vivo exposure to cetuximab in *KRAS/NRAS/BRAF<sup>V600</sup>* cells that were immunomagnetically separated from the serous effusions of patients with known cetuximab resistance.

**Results** Differences in levels of phospho-proteins in cetuximab sensitive and resistant cell lines included reductions in phospho-RPS6 and phospho-PRAS40 in cetuximab sensitive, but not cetuximab resistant cell lines at 1 and 4 h, respectively. In addition, phospho-AKT levels were found to be elevated in 3/4 patient samples following ex vivo incubation with cetuximab for 1 h. We further explored these findings by studying the effects of combinations of cetuximab and two PI3K pathway inhibitors in 3 cetuximab resistant cell lines. The addition of PI3K pathway inhibitors to cetuximab led to a significantly higher reduction in colony formation capacity compared to cetuximab alone.

**Conclusion** Our findings suggest activation of the PI3K pathway as a mechanism of cetuximab resistance in *KRAS/NRAS/BRAF<sup>V600</sup>* wild-type CRC.

**Keywords** Colorectal cancer · Cetuximab · Proteomics · Phospho-proteomics · Signalling adaptations · Resistance mechanisms

## Abbreviations

AKT	Serine-threonine protein kinase also called protein kinase B
ALK	Anaplastic lymphoma kinase
BRAF	V-raf murine sarcoma viral oncogene homolog B1
CCR7	C–C chemokine receptor type 7
CHK	Checkpoint kinase
C <sub>max</sub>	The peak serum concentration
EGFR	Epidermal growth factor receptor
ErbB	Family of proteins-contains four receptor tyrosine kinases, structurally related to the epidermal growth factor receptor
GI50	Growth inhibitory 50%
HER2	Human epidermal growth factor receptor 2
HER3	Human epidermal growth factor receptor 3
ICR	Institute of Cancer Research London UK
JAK	Janus Kinase

✉ Alexandros Georgiou  
a.georgiou@nhs.net

✉ Udai Banerji  
udai.banerji@icr.ac.uk

<sup>1</sup> Division of Cancer Therapeutics, The Institute of Cancer Research, Sycamore House, Downs Road, London SM2 5PT, UK

<sup>2</sup> Division of Molecular Pathology, The Institute of Cancer Research, Sycamore House, Downs Road, London SM2 5PT, UK

<sup>3</sup> Division of Clinical Studies, The Institute of Cancer Research, Sycamore House, Downs Road, London SM2 5PT, UK

<sup>4</sup> Department of Medicine, The Royal Marsden NHS Foundation Trust, Sycamore House, Downs Road, London SM2 5PT, UK

KRAS	Kirsten rat sarcoma viral oncogene
MAPK	Mitogen-activated protein kinase
MEK	Mitogen-activated protein kinase kinase
MET	MET proto-oncogene, receptor tyrosine kinase
MFI	Median fluorescent intensity
mTOR	Mammalian target of rapamycin
NRAS	Neuroblastoma ras viral oncogene homologue
NTRK	Neurotrophic-tropomyosin receptor kinase
PDGFR	Platelet growth factor receptor
PI3K	Phosphatidylinositol 3-kinase
PIK3CA	Phosphatidylinositol 3-kinase catalytic alpha polypeptide
PRAS40	He proline-rich Akt substrate of 40 kDa
ROS	Proto-oncogene tyrosine-protein kinase ROS
SD	Standard deviation
SRB	Sulforhodamine B
SRC	Proto-oncogene tyrosine-protein kinase Src
STAT	Signal transducer and activator of transcription protein
WT	Wild-type

## 1 Introduction

Cetuximab is a monoclonal antibody that targets the epidermal growth factor receptor (EGFR). As a single agent and in combination with cytotoxic agents, cetuximab has been shown to improve overall survival, when compared to placebo or standard of care, in patients with metastatic *KRAS* and *NRAS* exon 2–4 wild-type (WT) colorectal cancer (CRC) [1–3]. However, even in patients with *KRAS* WT tumours, with resistance to standard of care chemotherapy, the clinical efficacy of cetuximab is modest, with a monotherapy radiological response rate of 20% [1]. Evolutionary changes leading to the selection of the “fittest” *RAS* mutant resistant clones and other genetic aberrations such as *PIK3CA*, *BRAF* and extracellular *EGFR* domain mutations, *HER2* amplifications and *ALK/ROS1/NTRKs/RET* fusions have also been suggested as mechanisms of anti-EGFR antibody resistance [4–7]. In addition to genetic aberrations, compensatory signalling crosstalk (for example between EGFR and MET receptor or EGFR with other ErbB family receptors) have been suggested to contribute to the development of cetuximab resistance [6, 8].

Phospho-proteomic changes following exposure to targeted therapies can be regarded as a quantifiable surrogate of adaptive signalling. To date, no studies have been reported on the profiling of phospho-proteomic changes upon exposure to cetuximab in *KRAS/NRAS/BRAF*<sup>V600</sup> WT CRC cells. We hypothesised that studying re-wiring of signal transduction in response to cetuximab may provide novel insights into mechanisms of drug resistance in the setting of *RAS/BRAF*<sup>V600</sup> WT CRC. To test this hypothesis, we utilised

12 *KRAS/NRAS/BRAF*<sup>V600</sup> WT cell lines, representing both cetuximab sensitive and resistant cells, and patient-derived samples that were isolated from serous effusions of patients with *KRAS/NRAS/BRAF*<sup>V600</sup> WT CRC, who were resistant to cetuximab. We next used a multiplex antibody-based proteomic platform to quantify simultaneous changes in 55 phospho-proteins, following 1 and 4 h of cetuximab exposure. Our phospho-proteomic panel included 26 receptor and non-receptor tyrosine kinases as well as phospho-proteins that function within pathways that are known to be key in CRC, including the MAPK, PI3K, JAK-STAT and Wnt/ $\beta$ -Catenin pathways. All findings of interest were validated and further investigated.

## 2 Methods

### 2.1 Cell lines, tissue culture and anti-cancer agents

The SNUC1, CACO2 and LIM1215 cell lines were purchased from the American Tissue Culture Collection (ATCC) and the C10, C70 and HCA24 cell lines from Public Health England (PHE). The NCIH508, HCA46, SW48 and COLO320 cell lines were kindly donated by other laboratories within the Institute of Cancer Research (ICR) London. OXCO2 and DiFi were kindly donated by Professor Alberto Bardelli’s team, Candiolo Cancer Institute, Turin, Italy. The known mutations in the cell line panel are described in Supplementary Table 1. Cetuximab was kindly provided by Merck Serono Ltd., UK, an affiliate of Merck KGaA, Darmstadt, Germany. GDC0941 and AZD2014 were purchased from Selleck Chemicals.

### 2.2 Isolation of cancer cells from serous effusions of patients with *KRAS/NRAS/BRAF*<sup>V600</sup> WT CRC

Up to 1000 ml ascites or pleural fluid was collected from patients at the time of therapeutic drainage after which cancer cells were immunomagnetically separated on the same day using previously published methods [9, 10].


### 2.3 Quantification of phosphoproteins

#### 2.3.1 Luminex 200 magnetic bead suspension array

The material and methods used have been described previously [9]. All phospho-proteins that were quantified are listed in Supplementary Fig. 1. In brief, cells were equally seeded in 25 cm<sup>2</sup> flasks and cultured to 70% confluency. Next, the cells were exposed to cetuximab or left untreated for 1 and 4 h. To closely model the clinical setting, the concentration of cetuximab used (306  $\mu$ g/ml) was equal to the peak serum concentration ( $C_{\max}$ ) that cetuximab has been

**Fig. 1** *KRAS/NRAS/BRAF*<sup>V600</sup>

WT CRC cell line sensitivity to cetuximab. Mean GI<sub>50</sub> values are shown  $\pm$  standard error ( $n = 3$ ); data are representative of 3 independent experiments. Six cell lines (COLO320, SW48, SNUC1, HCA24, C10, CACO2) were classified as cetuximab resistant as a GI<sub>50</sub> was not reached at the highest cetuximab concentration used (1000  $\mu$ g/ml). Six cell lines (C70, OXCO2, DiFi, LIM1215, NCIH508, HCA46) were classified as sensitive with a mean GI<sub>50</sub> 0.063 ( $\pm 0.025$ )  $\mu$ g/ml. The difference between cetuximab sensitive and resistant cell lines was statistically significant (Mann Whitney test  $p = 0.0022$ )



reported to reach in patients' plasma in early phase clinical trials [11]. Since cetuximab protein binding in plasma is negligible, the  $C_{\max}$  concentration in cell culture was not modified [12]. After 1 or 4 h exposure, cells were lysed in 43–040 (MerckMillipore) supplemented with protease (I3786, Sigma Aldrich, UK) and phosphatase (4,906,845,001, Sigma Aldrich) inhibitors. Ten  $\mu$ g protein was loaded in each well of a 96-well plate and processed as per manufacturers' protocol. The quality control measures for our antibody-based multiplex platform have been previously described [9].

### 2.3.2 Quantification of proteins using Western blot analysis

Western blot analysis was carried out using standard techniques. The concentrations of the antibodies used are documented in Supplementary Table 2.

## 2.4 Cell proliferation assays

### 2.4.1 Sulforhodamine B (SRB) and CellTiter-Blue (CTB) assays

Cells were seeded in 96-well plates for 24 h before being treated with serial dilutions of the desired inhibitor, or vehicle control. The range of cetuximab concentrations used for the cell lines was 0.008 to 1000  $\mu$ g/ml. After 72 h, cells were fixed using 10% trichloroacetic acid, washed with double distilled water, air-dried and stained using 0.4% SRB in 1% acetic acid for 20 min. SRB was solubilized using 10 mM Tris–HCl and the absorbance was read at 570 nm wavelength using a Titertek Multiscan MCC/340 MKII plate reader. For non-adherent cell lines (SNUC1) a CellTiter-Blue assay was used. For this, cells were seeded and treated in same way as per SRB assay. After 72 h CellTiter-Blue reagent was added


at a 1:10 dilution and incubated for 4 h. Next, fluorescence was quantified using an EnVision plate reader. GI<sub>50</sub> values were calculated using GraphPad prism 8.0.

### 2.4.2 Clonogenic assay

Cells were seeded into 12-well plates ( $2.5 \times 10^3$  to  $7.5 \times 10^3$  /well) and 24 h later inhibitors were added to the cells and incubated for 14 days. A concentration of GDC0941 and AZD2014 of 100 nM was chosen based on preliminary experiments that confirmed downstream signalling inhibition at the chosen dose (e.g. pPRAS40 and pS6, see Supplementary Fig. 2). Next, cells were fixed with 4% formaldehyde/PBS for 20 min and stained with 0.5% crystal violet in 70% ethanol. Finally, plates were imaged using a GelCount (Oxford Optonix) system.

## 2.5 Statistical tests and interpretation of multiplex phospho-proteomics data

For each of the cell lines used for both the 1 and 4 h experiments, three control samples and one cetuximab sample were used. All phospho-proteomic data were normalised to GAPDH. The mean and standard deviation (SD) of the median fluorescent intensity (MFI) were calculated for the three controls. For each cell line, when the cetuximab treated value was  $> 2$  SDs above the mean of the controls it was classified as 'increased' and when it was  $< 2$  SDs below the mean of the controls it was classified as 'decreased'. If the cetuximab treated value was within 2 SDs of the mean of the controls it was considered unchanged. We chose to use this method for our cell line screens, as we did not validate



**Fig. 2** Changes in phospho-protein levels in cetuximab sensitive and resistant *KRAS/NRAS/BRAF*<sup>V600</sup> WT CRC cell lines. Phosphoprotein changes following 1 (a) and 4 (b) h cetuximab exposure. In red phospho-proteins whose expression is increased, defined as having a cetuximab treated value that was at least 2 S.D. above the mean of three untreated controls. In blue, phospho-proteins whose expression is decreased, defined as a cetuximab treated value of at least 2 S.D. below the mean of controls. In white, phospho-proteins that were

unchanged compared to controls. The black arrows indicate the phospho-protein changes that are statistically significant after Benjamini-Hochberg (BH) correction ( $p < 0.05$ ). Phosphorylated RPS6 expression was statistically more likely to be downregulated in cetuximab sensitive cell lines following 1 h cetuximab exposure. At 4 h exposure phospho-PRAS40 was more likely to be decreased in sensitive cell lines, whereas pPDGFRα and pCHK2 were more likely to be increased in cetuximab resistant cell lines

the linearity of the absolute changes in phospho-proteins in our assays.

For the ex vivo patient sample experiments, due to limited cell numbers, both 1 and 4 h experiments were not possible. Therefore, we were only able to carry out 1 h exposure experiments. The ex vivo experiments were otherwise conducted in the same way as the cell line experiments. For each patient sample we included 3 untreated controls and one drug exposed sample. Then the ratios of the cetuximab treated to untreated controls were calculated using the following equation: ratio of change = MFI of cetuximab treated sample / mean MFI of three controls. A phospho-protein with a ratio > 1 meant that there was an increase in phospho-protein expression compared to the controls, and the reverse was true if the ratio was < 1.

Differences in  $GI_{50}$  between sensitive and resistant cell lines were analysed using a Mann Whitney test (GraphPad Prism 8.0). Statistical differences in phospho-proteomic

changes following exposure to cetuximab between cetuximab sensitive and resistant cell lines were studied using Binary Logistic regression corrected for False Discovery Rate (FDR) via the Benjamini-Hochberg (BH) procedure. Differences between readouts of clonogenic assays of cells treated with cetuximab, GDC0941, AZD2014 or the combination were analysed using  $t$  tests (GraphPad Prism 8.0).

### 3 Results and discussion

Six cell lines (COLO320, SW48, SNUC1, HCA24, C10 and CACO2) were classified to be cetuximab resistant, as a  $GI_{50}$  was not reached at any concentration, with the highest cetuximab concentration used being 1000 µg/ml. Another six cell lines (C70, OXCO2, DiFi, NCIH508, LIM1215 and HCA46) were classified as cetuximab sensitive; mean ( $\pm$  S.E) cetuximab  $GI_{50}$  0.063 ( $\pm$  0.025) µg/ml. The cetuximab  $GI_{50}$

difference between sensitive and resistant groups was significant ( $p=0.0022$ , Fig. 1).

A number of phospho-proteins was found to be differentially regulated in the cetuximab sensitive versus resistant cell lines following 1 and 4 h exposure to 306 µg/ml cetuximab, a concentration that was clinically achievable in  $C_{max}$  concentration trials [11]. Binary logistic regression and adjustments for multiple testing were applied to test for changes that were statistically significant (Fig. 2). A decrease in phospho-RPS6 levels was statistically more likely to occur in cetuximab sensitive cell lines following 1 h of cetuximab exposure ( $p=0.04$ ). After a 4 h exposure another closely related PI3K pathway phospho-protein, phospho-PRAS40, was more likely to be decreased in cetuximab sensitive compared to resistant cell lines ( $p=0.04$ ). Conversely, phospho-PDGFRα and phospho-CHK2 were found more likely to be increased in cetuximab resistant versus sensitive cell lines ( $p=0.04$  and  $p=0.03$ , respectively). Interestingly, phospho-EGFR levels were reduced in both cetuximab sensitive and resistant cell lines at a comparable level, which suggests that cetuximab continued to inhibit its intended target and that differences in sensitivity were possibly related to downstream signalling.

In 4 patient-derived samples, cells were immunomagnetically isolated from serous effusions. The clinical history of all 4 patients was suggestive of resistance to cetuximab (Fig. 3a). Changes in all phospho-proteins following cetuximab exposure are presented as ratios of changes compared to the untreated controls (Fig. 3b). The 1 h patient sample and cetuximab resistant cell line results were largely concordant. For example, a lack of reduction in phospho-RPS6 in 3 of 4 patient samples following exposure to cetuximab was seen in both resistant cell lines and patient samples. Interestingly, an increase in phospho-AKT<sup>Ser473</sup> levels was seen in 3 out of 4 patient samples following exposure to cetuximab, suggesting continued activation of the PI3K pathway.

In view of the findings in the cell lines which showed that phospho-RPS6 and phospho-PRAS40 levels were not reduced in response to cetuximab in the cetuximab resistant cell lines, when compared to the cetuximab sensitive cell lines, and the finding that phospho-AKT<sup>Ser473</sup> was increased in 3 out of 4 CRC samples exposed to cetuximab ex vivo for 1 h, we decided to explore the effects of the addition of PI3K pathway inhibitors to cetuximab in cetuximab resistant cell lines. Three cetuximab resistant cell lines (C10, SW48 and CACO2) were exposed to 100 nM pictilisib (also known as GDC0941, a PI3K inhibitor) and vistusertib (also known as AZD2014, a m-TORC1/2 inhibitor). Inhibition of phospho-RPS6 and phospho-PRAS40 was confirmed at these concentrations. We also conducted single agent and combination therapies and subsequently applied Western blot analyses to SW48 and CACO2 cell lines (Supplementary Fig. 2). Down-regulation of the PI3K pathway and induction of apoptosis

in the combination experiments in excess of that seen with single agents was modest and was not consistent across all cell lines. We also investigated the effects of the combination of 10 µg/ml cetuximab and the two PI3K pathway inhibitors using 14 day clonogenic assays. We observed a statistically significant higher inhibition of colony forming capacity following the addition of PI3K pathway inhibitors to cetuximab, when compared to single agent exposure, in all three cetuximab resistant cell lines (Fig. 4).

The role of *KRAS/NRAS* mutations in cetuximab resistance is well-documented and they lead to continued signalling downstream of EGFR through the PI3K and MEK-ERK pathways [13, 14]. The response rates of cetuximab monotherapy in patients with chemotherapy resistant *KRAS* WT CRC is, however, only ~20% and therefore there remains an unmet need to improve their clinical outcome [1]. We aimed to investigate the role of signalling adaptations by determining sensitivity to cetuximab in *KRAS/NRAS/BRAF*<sup>V600</sup> WT CRCs. This is the first report of an antibody-based phospho-proteomic screen of dynamic changes in signal transduction ex vivo in cancer cells derived from patients with cetuximab resistant tumours. However, we had access to only a limited number of samples. Indeed, current literature suggests that patients with *KRAS* mutant tumours are more likely to develop serous effusions, a phenomenon that we also observed before [15, 16]. This may have contributed to the relatively small number of samples of cells isolated from patients with *KRAS/NRAS/BRAF*<sup>V600</sup> WT tumours that we were able to include.

Previous studies that investigated adaptations in signalling pathways as a mechanism of resistance to cetuximab suggested activation of receptor tyrosine kinases such as HER3 and non-receptor kinases such as SRC [17, 18]. While in our screen phospho-HER3 and SRC levels were increased in a number of cetuximab resistant cell lines following 1 h and 4 h of cetuximab exposure, respectively, the results were not statistically significant upon correction for multiple testing. This may at least in part have been due to differences between the cell lines and patient samples used. For example, in studies identifying SRC as a regulator of cetuximab sensitivity/resistance, *KRAS* mutant cell lines such as HCT116 and HT29 were used [18]. Instead in our data set, when corrected for multiple testing, only 4 changes were significant of which two (phospho-RPS6 and phospho-PRAS40) were related to the PI3K pathway. We speculate that in different cetuximab resistant cells, different receptor and non-receptor tyrosine kinases may be activated, with co-activation of several receptors being likely. This may subsequently result in the observed PI3K pathway upregulation. Indeed 3/4 of our samples isolated from CRC patients with established cetuximab resistance showed increases in phospho-AKT levels when exposed ex vivo to cetuximab. We subsequently investigated the



A								
ID	Age	Primary Site	Ascites (A) or Pleural effusion (P)	KRAS	NRAS	BRAF	Lines of Systemic Therapy at sampling	Cetuximab Best Response
1	55	Rectum	A	WT	WT	WT	1.FOLFOX+ Bevacizumab 2.FOLFIRI+ Cetuximab 3.Regorafenib	Acquired Resistance
2	41	Caecum	A	WT	WT	WT	Untreated	Primary Resistance
3	63	Caecum	A	WT	WT	WT	1.FOLFOX + Cetuximab	Primary Resistance
4	76	Rectum	P	WT	WT	WT	1.FOLFIRI+ Cetuximab 2.Raltitrexed +Oxaliplatin 3.Tipiracil/ Trifluridine	Primary Resistance

B	p-protein	Patient sample ID			
		1	2	3	4
RTK and non receptor kinases	VEGFR1	0.93	0.95	1.05	0.97
	VEGFR2	0.99	1.03	1.14	0.91
	VEGFR3	1.41	0.78	1.69	0.83
	TIE1	0.88	1.13	1.20	1.33
	TIE2	0.96	1.31	1.02	1.03
	PDGFRa (pan TYR)	1.12	1.19	1.31	0.95
	PDGFRb (pan TYR)	1.10	0.81	1.12	1.28
	PDGFRa	0.90	0.97	1.30	0.97
	PDGFRb	0.92	1.05	1.50	0.92
	EGFR	1.07	0.92	1.02	0.87
	HER2	0.99	1.39	0.91	0.99
	HER3	1.11	0.94	0.88	1.03
	HER4	1.00	0.97	0.86	1.19
	cKIT	1.15	1.18	1.15	0.92
	cMET	0.83	0.79	1.43	0.73
	IGF1R (pan TYR)	1.17	1.05	1.13	1.02
	IGF1R	0.94	0.98	1.35	0.78
	IR (pan TYR)	1.24	0.97	0.91	0.99
	IR	1.60	0.92	0.83	0.91
	IRS1	1.16	1.36	1.37	0.87
	AXL	1.24	0.94	1.24	1.03
	RET	1.10	0.77	1.08	1.04
	FGFR1(pan TYR)	0.93	1.12	1.19	0.96
	FGFR1	0.78	3.63	1.10	0.96
	FGFR2	0.93	0.88	1.12	1.01
	FGFR3	1.02	0.84	1.09	0.96
JNK Pathway	FLT3	0.89	1.18	1.23	1.03
	SRC	1.08	1.14	1.42	0.91
	FAK	1.06	0.73	1.10	0.78
	JNK	0.81	0.92	0.91	1.00
PI3K-AKT-mTOR Pathway	cJUN	1.05	0.57	1.65	1.11
	ATF2	0.89	1.68	0.79	0.73
	AKT308	0.83	0.85	1.15	1.05
	AKT473	1.63	2.53	1.74	0.92
MAPK Pathway	PRAS40	0.67	1.52	1.00	0.87
	mTOR	0.86	1.66	0.84	0.83
	p70S6K	1.00	1.45	0.72	0.95
	RPS6	1.00	1.23	0.88	1.02
	GSK3a	0.97	0.96	1.33	0.97
	GSK3B	1.06	0.96	1.02	0.97
	TSC2	0.92	1.73	1.15	0.86
	PTEN	1.19	0.64	1.12	1.44
	βCATENIN	0.85	1.03	1.10	0.93
	cRAF	0.94	0.83	1.12	1.09
JAK-STAT Pathway	MEK1	0.53	0.64	0.93	1.18
	ERK/MAPK	0.99	1.16	1.09	1.37
	p38	1.02	0.89	0.83	1.06
	MSK1	0.80	1.17	1.13	0.99
DNA Damage Cell Cycle	JAK1	0.92	0.66	1.10	1.27
	STAT1	0.81	1.22	0.74	1.16
	STAT3	1.05	0.72	0.92	0.99
	STAT5	1.00	1.03	1.03	0.92
Immune system	HSP27	0.91	0.85	0.68	1.50
	CHK1	0.94	0.87	1.24	1.03
	CHK2	1.62	0.92	1.00	0.95
	p53	0.98	1.08	0.96	1.13
Immune system	Rb	0.96	0.97	1.18	0.83
	NFκB	1.20	1.13	0.89	0.62
	LCK	0.78	0.97	1.15	1.00
Immune system	MCSFR	0.94	0.90	1.55	1.00

**Fig. 3** Clinical features and phospho-proteomic changes in cancer cells isolated from ascites/pleural effusions. **a:** Clinicopathological characteristics of patients at the time of sample collection, including the lines of systemic therapy received. Mutation data are based on standard diagnostics carried out on primary tumour samples. **b:** Cells were immunomagnetically isolated from patients' serous effusions and were treated ex vivo with 306 µg/ml cetuximab or left untreated (n=4) for 1 h. Mean ratios of change (cetuximab treated to untreated controls) for all phospho-proteins quantified in 4 *KRAS*/

*NRAS/BRAF*<sup>V600</sup> wild-type CRC patient samples are shown. A ratio >1 (in red) suggests increase in phospho-protein expression in the cetuximab treated cells compared to the mean of controls and a ratio <1 (blue) the reverse. A lack of reduction in phospho-RPS6 in 3 of 4 patient samples following exposure to cetuximab was observed (lower arrow). In addition, an increase in phospho-AKT Ser473 levels was observed in 3 of 4 cell patient samples (upper arrow) following exposure to cetuximab, suggesting continued activation of the PI3K pathway


effects of the combination of PI3K pathway inhibitors with cetuximab in three cetuximab resistant cell lines and observed additional growth inhibition when compared to single agent treatment activity.

Activation of the PI3K pathway in *KRAS* mutated CRC has been reported before [9, 19], but little is known about this in the *KRAS/NRAS/BRAF*<sup>V600</sup> WT setting [20]. Factors that have been thought to be important in a *KRAS/BRAF*<sup>V600</sup> WT setting include CCR7 expression [21] and mutations in genes regulating the PI3K pathway [22]. In contrast, another study has suggested that signalling through the PI3K

pathway may confer a better response to anti-EGFR pathway treatment in this setting [23].

Other groups have previously suggested that PI3K pathway inhibitors such as PI3K, AKT and m-TOR inhibitors may be effective when combined with cetuximab, which is in agreement with our current data [24, 25]. Clinical trials have explored the combination of PI3K pathway inhibitors (e.g. PX-886) with cetuximab in the *KRAS* WT setting without any improvement in clinical efficacy, but with increased toxicity in the combination over cetuximab alone [26]. On the other hand, a clinical trial that investigated addition of the m-TOR inhibitor everolimus to cetuximab and irinotecan

**Fig. 4** Growth inhibition caused by combination of cetuximab and PI3K pathway inhibitors. Two-week clonogenic assays in 3 cetuximab resistant cell lines, C10, SW48, CACO2. All cells were treated with 10 µg/ml cetuximab. **a:** Combination with 100 nM GDC-0941; **b:** Combination with 100 nM AZD2014. Images are representative of 3 repeats. The mean (± S.E.) reduction of total area density in relation to the control is shown (n=3) for each treatment condition, along with *t*-test analysis



in 43 patients suggested that the combination was clinically active and that it should be further developed [27]. Combinations of PI3K pathway inhibitors and cetuximab in the *KRAS/NRAS/BRAF*<sup>V600</sup> WT setting should be explored in vivo along with biomarkers (e.g. PTEN loss) that may further enrich clinical benefit. These efforts may lead to combinations which are clinically actionable.

Our phospho-proteomic screen, though not extensive, did uncover actionable signalling nodes from multiple

different signal transduction pathways such as receptor tyrosine kinases (RAS-RAF-MEK, PI3K-AKT-m-TOR), angiogenesis receptors (JAK-STAT, WNT) and DNA damage repair pathways (supplementary Fig. 1). It is of interest to note that upon correction for multiple testing it was mainly the PI3K pathway that showed differences in signalling between cetuximab sensitive and resistant lines at early time points. This offers insights into differences in dependencies on signal transduction pathways between

cetuximab resistant and sensitive *KRAS/NRAS/BRAF*<sup>V600</sup> WT CRC.

We also report dynamic signalling patterns in freshly isolated cancer cells from serous effusions in patients with *KRAS/NRAS/BRAF*<sup>V600</sup> WT CRC who were resistant to cetuximab therapy. Though the number of samples was small, it was encouraging to see concordance between activation of the PI3K pathway between the cell lines and patient samples in the assays studying early changes in dynamic signal transduction.

We acknowledge some limitations of our work. All cell lines were cultured to 70% confluency before 1 or 4 h exposure to control or cetuximab. This may have led to differences in the actual cell numbers seeded between cell lines at the time of cetuximab dosing. This was compensated by seeding equal amounts of protein in our phospho-proteomic experiments for all cell lines and patient samples used. Moreover, all phospho-proteomic results were adjusted for loading using GAPDH. In our 25 cell line 1 and 4 h cetuximab exposure experiments and in our 1 h ex vivo patient sample experiments, one cetuximab exposed and three untreated control samples were used. This was compensated by our strict definition of a 'hit' in our phospho-proteomic analysis. A significantly altered phospho-protein expression was defined as a treated value of 2 standard deviations above or below the mean of the three controls. Moreover, when comparing cetuximab sensitive and resistant cells, our statistical analysis for significance included adjustment for multiple testing. Lastly, the patient sample genomic data were derived from analysis of the primary tumours and this was not confirmed in the malignant cells isolated from the serous effusions. We acknowledge that tumour heterogeneity and effects of previous treatments may have affected these genomic aberrations. Nevertheless, there is evidence to suggest that there is high genomic concordance between matched primary and metastatic CRC samples [28].

In conclusion, our phospho-proteomic study of acute rewiring of signal transduction, following exposure to clinically relevant concentrations of cetuximab, in a panel of *KRAS/NRAS/BRAF*<sup>V600</sup> WT cell lines and ex vivo in samples derived from patients with clinical resistance to cetuximab, strongly suggests continued activation of the PI3K pathway as a mechanism of resistance to cetuximab. Combinations of PI3K pathway inhibitors and cetuximab in the *KRAS/NRAS/BRAF*<sup>V600</sup> WT setting should be explored in vivo, which may lead to combinations that are clinically actionable.

**Supplementary Information** The online version contains supplementary material available at <https://doi.org/10.1007/s13402-021-00628-7>.

**Acknowledgements** The authors acknowledge funding from the National Institute of Health (NIHR) Biomedical Research Centre (BRC) and Experimental Cancer Medicine Centre (ECMC) initiatives at The Institute of Cancer Research and The Royal Marsden Hospital

NHS Foundation trust. UB is a recipient of a NIHR research professorship award (ref RP-2016-07-028).

**Authors' contributions** Conceptualization: A.G., S.W. and U.B.; methodology: A.G., A.S., S.W. and U.B.; data collection: A.G., A.S. G.V. and L.P.; data analysis: A.G., A.S., L.P. and G.V.; writing-original draft preparation: A.G.; writing-review and editing: A.G., A.S., G.V., D.C., N.V., S.W. and U.B.; supervision: S.W. and U.B.

**Funding** This work was supported by a Cancer Research UK grant awarded to A.G. for a clinical research fellowship at The Institute of Cancer Research.

## Declarations

**Conflict of interest** A.G., A.S., G.V., L.P. and S.W. declare no conflicts of interest. D.C. has received grants from 4SC, Amgen, AstraZeneca, Bayer, Celgene, Clovis, Eli Lilly, Janssen, Medimmune, Merck, Merimack and Sanofi outside the submitted work. N.V. received honoraria and/or travel accommodation from Merck Serono, Pfizer, Bayer, Eli Lilly and Menarini Silicon Biosystems and U.B. has received honoraria from Astellas, Novartis, Karus Therapeutics, Phoenix Solutions, Eli Lilly, Astex, Vernalis, Janssen and Boehringer Ingelheim. His institutional financial interests include funding for Phase I investigator-initiated trials from Onyx Pharmaceuticals, BTG International, Carrick Therapeutics, Chugai, AstraZeneca and Verastem. He is an employee of the Institute of Cancer Research, London, which is involved in the development of PI3K, HSP90, HDAC, AKT, ROCK, RAF, CHK1 and HSF1 inhibitors.

**Ethical approval** The study was carried out in accordance with the declaration of Helsinki and approved by a human research ethics committee.

**Informed consent** All patients provided written informed consent prior to their participation.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

## References

1. T.J. Price, M. Peeters, T.W. Kim, J. Li, S. Cascinu, P. Ruff, A.S. Suresh, A. Thomas, S. Tjulandin, K. Zhang, S. Murugappan, R. Sidhu, Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. *Lancet Oncol.* **15**, 569–579 (2014). [https://doi.org/10.1016/S1470-2045\(14\)70118-4](https://doi.org/10.1016/S1470-2045(14)70118-4)
2. C. Bokemeyer, E. Van Cutsem, P. Rougier, F. Ciardiello, S. Heeger, M. Schlichting, I. Celik, C.H. Kohne, Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type



- metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. *Eur. J. Cancer* **48**, 1466–1475 (2012). <https://doi.org/10.1016/j.ejca.2012.02.057>
3. E. Van Cutsem, C.H. Kohne, I. Lang, G. Folprecht, M.P. Nowacki, S. Cascinu, I. Shchepotin, J. Maurel, D. Cunningham, S. Tejpar, M. Schlichting, A. Zube, I. Celik, P. Rougier, F. Ciardiello, Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. *J. Clin. Oncol.* **29**, 2011–2019 (2011). <https://doi.org/10.1200/JCO.2010.33.5091>
4. K.H. Khan, D. Cunningham, B. Werner, G. Vlachogiannis, I. Spiteri, T. Heide, J.F. Mateos, A. Vatsiou, A. Lampis, M.D. Dama-vandi, H. Lote, I.S. Huntingford, S. Hedayat, I. Chau, N. Tunariu, G. Mentrasti, F. Trevisani, S. Rao, G. Anandappa, D. Watkins, N. Starling, J. Thomas, C. Peckitt, N. Khan, M. Rugge, R. Begum, B. Hezelova, A. Bryant, T. Jones, P. Proszek, M. Fassan, J.C. Hahne, M. Hubank, C. Braconi, A. Sottoriva, N. Valeri, Longitudinal liquid biopsy and mathematical modeling of clonal evolution forecast time to treatment failure in the PROSPECT-C phase II colorectal cancer clinical trial. *Cancer Discov.* **8**, 1270–1285 (2018). <https://doi.org/10.1158/2159-8290.Cd-17-0891>
5. R. Dienstmann, L. Vermeulen, J. Guinney, S. Kopetz, S. Tejpar, J. Tabernero, Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. *Nat. Rev. Cancer* **17**, 268 (2017). <https://doi.org/10.1038/nrc.2017.24>
6. R. Dienstmann, R. Salazar, J. Tabernero, Overcoming Resistance to Anti-EGFR Therapy in Colorectal Cancer. *Am. Soc. Clin. Oncol. Educ. Book* **35**, e149–156 (2015). [https://doi.org/10.14694/EdBook\\_AM.2015.35.e149](https://doi.org/10.14694/EdBook_AM.2015.35.e149)
7. F. Morano, S. Corallo, S. Lonardi, A. Raimondi, C. Cremolini, L. Rimassa, R. Murialdo, A. Zaniboni, A. Sartore-Bianchi, G. Tomasello, P. Racca, M. Clavarezza, V. Adamo, F. Perrone, A. Gloghini, E. Tamborini, A. Busico, A. Martinetti, F. Palermo, F. Loupakis, M. Milione, G. Fuca, M. Di Bartolomeo, F. de Braud, F. Pietrantonio, Negative hyperselection of patients with RAS and BRAF wild-type metastatic colorectal cancer who received panitumumab-based maintenance therapy. *J. Clin. Oncol.* **37**, 3099–3110 (2019). <https://doi.org/10.1200/jco.19.01254>
8. A. Bardelli, S. Corso, A. Bertotti, S. Hobor, E. Valtorta, G. Siravegna, A. Sartore-Bianchi, E. Scala, A. Cassingena, D. Zecchin, M. Apicella, G. Migliardi, F. Galimi, C. Lauricella, C. Zanon, T. Perera, S. Veronese, G. Corti, A. Amatu, M. Gambacorta, L.A. Diaz Jr., M. Sausen, V.E. Vulculescu, P. Comoglio, L. Trusolino, F. Di Nicolantonio, S. Giordano, S. Siena, Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. *Cancer Discov.* **3**, 658–673 (2013). <https://doi.org/10.1158/2159-8290.CD-12-0558>
9. A. Stewart, E.A. Coker, S. Polsterl, A. Georgiou, A.R. Minchom, S. Carreira, D. Cunningham, M.E.R. O'Brien, F.I. Raynaud, J.S. de Bono, B. Al-Lazikani, U. Banerji, Differences in signaling patterns on PI3K inhibition reveal context specificity in KRAS-mutant cancers. *Mol. Cancer Ther.* (2019). <https://doi.org/10.1158/1535-7163.Mct-18-0727>
10. C.P. Carden, A. Stewart, P. Thavasu, E. Kipps, L. Pope, M. Crespo, S. Miranda, G. Attard, M.D. Garrett, P.A. Clarke, P. Workman, J.S. de Bono, M. Gore, S.B. Kaye, U. Banerji, The association of PI3 kinase signaling and chemoresistance in advanced ovarian cancer. *Mol. Cancer Ther.* **11**, 1609–1617 (2012). <https://doi.org/10.1158/1535-7163.Mct-11-0996>
11. J. Tabernero, F. Ciardiello, F. Rivera, E. Rodriguez-Braun, F.J. Ramos, E. Martinelli, M.E. Vega-Villegas, S. Rosello, S. Liebscher, O. Kisker, T. Macarulla, J. Baselga, A. Cervantes, Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study. *Ann. Oncol.* **21**, 1537–1545 (2010). <https://doi.org/10.1093/annonc/mdp549>
12. C. Delbaldo, J.Y. Pierga, V. Dieras, S. Faivre, V. Laurence, J.C. Vedovato, M. Bonnay, M. Mueser, A. Nolting, A. Kovar, E. Raymond, Pharmacokinetic profile of cetuximab (Erbix) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinoma. *Eur. J. Cancer* **41**, 1739–1745 (2005). <https://doi.org/10.1016/j.ejca.2005.04.029>
13. J.Y. Fang, B.C. Richardson, The MAPK signalling pathways and colorectal cancer. *Lancet Oncol.* **6**, 322–327 (2005). [https://doi.org/10.1016/s1470-2045\(05\)70168-6](https://doi.org/10.1016/s1470-2045(05)70168-6)
14. E. Van Cutsem, H.J. Lenz, C.H. Kohne, V. Heinemann, S. Tejpar, I. Melezinek, F. Beier, C. Stroh, P. Rougier, J.H. van Krieken, F. Ciardiello, Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. *J. Clin. Oncol.* **33**, 692–700 (2015). <https://doi.org/10.1200/jco.2014.59.4812>
15. T. Agaloti, A.D. Giannou, A.C. Krontira, N.I. Kanellakis, D. Kati, M. Vreka, M. Pepe, M. Spella, I. Lilis, D.E. Zazara, E. Nikolouli, N. Spiropoulou, A. Papadakis, K. Papadia, A. Voulgaridis, V. Harokopos, P. Stamou, S. Meiners, O. Eickelberg, L.A. Snyder, S.G. Antimisiaris, D. Kardamakis, I. Psallidas, A. Marazioti, G.T. Stathopoulos, Mutant KRAS promotes malignant pleural effusion formation. *Nat. Commun.* **8**, 15205 (2017). <https://doi.org/10.1038/ncomms15205>
16. A. Georgiou, A. Stewart, P. Thavasu, E.A. Coker, S. Poelsterl, B. Al-Lazikani, D. Cunningham, S. Whittaker and U. Banerji, 10—KRAS mutant and RAS/BRAF wild type colorectal cancer cells exhibit differences in the rewiring of signal transduction that can impact on future therapeutic strategies. *Ann. Oncol.* **29**, viii1 (2018). <https://doi.org/10.1093/annonc/mdy268>
17. A. Bosch-Vilaro, B. Jacobs, V. Pomella, L. Abbasi Asbagh, R. Kirkland, J. Michel, S. Singh, X. Liu, P. Kim, G. Weitsman, P.R. Barber, B. Vojnovic, T. Ng and S. Tejpar, Feedback activation of HER3 attenuates response to EGFR inhibitors in colon cancer cells. *Oncotarget* **8**, 4277–4288 (2017). <https://doi.org/10.18632/oncotarget.13834>
18. Y. Abe, M. Nagano, T. Kuga, A. Tada, J. Isoyama, J. Adachi, T. Tomonaga, Deep phospho- and phosphotyrosine proteomics identified active kinases and phosphorylation networks in colorectal cancer cell lines resistant to cetuximab. *Sci. Rep.* **7**, 10463 (2017). <https://doi.org/10.1038/s41598-017-10478-9>
19. S. Kasper, H. Reis, S. Ziegler, S. Nothdurft, A. Mueller, M. Goetz, M. Wiesweg, J. Phasue, S. Ting, S. Wiczorek, A. Even, K. Worm, M. Pogorzelski, S. Breitenbuecher, J. Meiler, A. Paul, T. Trarbach, K.W. Schmid, F. Breitenbuecher, M. Schuler, Molecular dissection of effector mechanisms of RAS-mediated resistance to anti-EGFR antibody therapy. *Oncotarget* **8**, 45898–45917 (2017). <https://doi.org/10.18632/oncotarget.17438>
20. M. Scartozzi, R. Giampieri, E. Maccaroni, A. Mandolesi, S. Biagetti, S. Alfonsi, L. Giustini, C. Loretelli, L. Faloppi, A. Bittoni, M. Bianconi, M. Del Prete, I. Bearzi, S. Cascinu, Phosphorylated AKT and MAPK expression in primary tumours and in corresponding metastases and clinical outcome in colorectal cancer patients receiving irinotecan-cetuximab. *J. Transl. Med.* **10**, 71 (2012). <https://doi.org/10.1186/1479-5876-10-71>
21. L. Gao, J. Xu, G. He, J. Huang, W. Xu, J. Qin, P. Zheng, M. Ji, W. Chang, L. Ren, Y. Wei, J. Xu, C. Liang, CCR7 high expression leads to cetuximab resistance by cross-talking with EGFR pathway in PI3K/AKT signals in colorectal cancer. *Am. J. Cancer Res.* **9**, 2531–2543 (2019)
22. S.M. Bray, J. Lee, S.T. Kim, J.Y. Hur, P.J. Ebert, J.N. Calley, I.H. Wulur, T. Gopalappa, S.S. Wong, H.R. Qian, J.C. Ting, J. Liu, M.D. Willard, R.D. Novosiadly, Y.S. Park, J.O. Park, H.Y. Lim, W.K. Kang, A. Aggarwal, H.C. Kim, C. Reinhard, Genomic characterization of intrinsic and acquired resistance to cetuximab

- in colorectal cancer patients. *Sci. Rep.* **9**, 15365 (2019). <https://doi.org/10.1038/s41598-019-51981-5>
23. A. Lièvre, B. Ouine, J. Canet, A. Cartier, Y. Amar, W. Cacheux, O. Mariani, R. Guimbaud, J. Selves, T. Lecomte, S. Guyétant, I. Bieche, F. Berger, L. de Koning, Protein biomarkers predictive for response to anti-EGFR treatment in RAS wild-type metastatic colorectal carcinoma. *Br. J. Cancer* **117**, 1819–1827 (2017). <https://doi.org/10.1038/bjc.2017.353>
  24. J.S. Kim, J.E. Kim, K. Kim, J. Lee, J.O. Park, H.Y. Lim, Y.S. Park, W.K. Kang, S.T. Kim, The impact of cetuximab plus AKT- or mTOR- inhibitor in a patient-derived colon cancer cell model with wild-type RAS and PIK3CA mutation. *J. Cancer* **8**, 2713–2719 (2017). <https://doi.org/10.7150/jca.19458>
  25. V. D'Amato, R. Rosa, C. D'Amato, L. Formisano, R. Marciano, L. Nappi, L. Raimondo, C. Di Mauro, A. Servetto, C. Fusciello, B.M. Veneziani, S. De Placido, R. Bianco, The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models. *Br. J. Cancer* **110**, 2887–2895 (2014). <https://doi.org/10.1038/bjc.2014.241>
  26. D.W. Bowles, M. Kochenderfer, A. Cohn, L. Sideris, N. Nguyen, V. Cline-Burkhardt, I. Schnadig, M. Choi, L. Nabell, A. Chaudhry, R. Ruxer, A. Ucar, D. Hausman, L. Walker, A. Spira, A. Jimeno, A. Randomized, Phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-Kinase inhibitor. *Patient. Metastat. Colorectal Carcinoma Clin. Colorectal Cancer* **15**, 337–344.e332 (2016). <https://doi.org/10.1016/j.clcc.2016.03.004>
  27. E.G. Chiorean, J. Picus, T. Breen, R.H. Ansari, W.A. Harb, M. Burns, A.J. Spittler, P.J. Loehrer, Phase I/II study of everolimus (E) with irinotecan (Iri) and cetuximab (C) in 2nd line metastatic colorectal cancer (mCRC): Hoosier Cancer Research Network GI05-102. *J. Clin. Oncol.* **33**, 3618–3618 (2015). [https://doi.org/10.1200/jco.2015.33.15\\_suppl.3618](https://doi.org/10.1200/jco.2015.33.15_suppl.3618)
  28. A.R. Brannon, E. Vakiani, B.E. Sylvester, S.N. Scott, G. McDermott, R.H. Shah, K. Kania, A. Viale, D.M. Oschwald, V. Vacic, A.K. Emde, A. Cercek, R. Yaeger, N.E. Kemeny, L.B. Saltz, J. Shia, M.I. D'Angelica, M.R. Weiser, D.B. Solit, M.F. Berger, Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions. *Genom. Biol.* **15**, 454 (2014). <https://doi.org/10.1186/s13059-014-0454-7>

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.